Therapeutic Solutions advances its COVID-19 stem cell-based therapy

By The Science Advisory Board staff writers

May 21, 2021 -- Therapeutic Solutions International announced new data and a patent filing demonstrating that lithium carbonate augments the scar-inhibiting activity of its JadiCell universal donor stem cell therapy.

In double-blind, placebo-controlled clinical trial, JadiCell was successful at substantially improving survival in end-stage patients with acute lung failure associated with COVID-19. The treatment was associated with significantly improved patient survival, serious adverse event-free survival, and time to recovery.

The company plans to initiate a phase III pivotal registration trial and seek marketing approval for use of JadiCell in acute respiratory distress syndrome and other lung diseases.

Therapeutic Solutions to use immunotherapy for COVID-19
Therapeutic Solutions plans to develop its clinical stage cancer immunotherapy treatment StemVacs for treatment of COVID-19 patients.

Copyright © 2021

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter